Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis

In conclusion, our findings suggest that daratumumab induces not only depletion of autoreactive long-lived plasma cells associated with improvements of neurological sequelae, but also severe side effects requiring clinical studies investigating efficacy and safety of anti-CD38 therapy in a ntibody-driven autoimmune encephalitis.
Source: Journal of Neurology - Category: Neurology Source Type: research